NCT05868915终止1 期
A Phase I/II Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of HV-101 Injection for the Patients With Recurrent or Metastatic Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Safety of HV-101
研究概览
简要总结
Background:
Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients. TIL therapy has shown strong efficacy for the treatment of solid tumors, and has achieved high objective response rates in multiple cancers.
Objective:
To evaluate the safety and efficacy of HV-101 for the treatment of advanced solid tumors.
Eligibility:
Adults aging 18-75 with advanced solid tumors
Design:
- Patients will undergo screening tests, including imaging procedures, heart and lung tests, and lab tests.
- Freshly resected patient tumors were dissected by the surgeon.
- TIL cells were isolated from the patient's tumor tissue in the laboratory, then cultured in vitro, activated and expanded.
- HV-101 will be re-infused into the patient.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be able to understand and sign the Informed of Consent Document. Be willing to follow the procedure and protocol of the clinical trial.
- •Age ≥ 18 years and ≤ 75 years.
- •Expected survival time > 3 months.
- •ECOG score 0-
- •At least one lesion that could undergo surgery or biopsy to obtain tumor tissue for TIL preparation
- •At least 1 measurable lesion (according to RECIST v1.1).
- •Metastatic or recurrent solid tumors confirmed by histopathology. Refractory to standard treatment evaluated by radiological assessment.
- •Hematology should at least meet the following criteria:
- •Absolute neutrophil count (ANC) ≥ 1.5× 109/L；
- •Platelet (PLT） ≥ 75× 109/L；
- •Hemoglobin (HGB) ≥ 90 g/L.
- •Liver and kidney function are normal:
- •Serum creatinine (Cr) ≤ 1.5 times of upper limit of normal (ULN) or creatine clearance ≥ 60 ml/min;
- •Serum Alanine aminotransferase (ALT) or/and Aspartate aminotransferase (AST) ≤ 2.5 times of ULN;
- •Total bilirubin (TBIL) ≤ 1.5 times of ULN.
- •Blood coagulation function is normal:
- •Prothrombin time (PT) ≤ 1.5 ULN;
- •International Normalized Ratio (INR) ≤ 1.5 ULN;
- •or Activated Partial Thromboplastin Time (APTT) ≤ 1.5 ULN.
- •Women of childbearing potential should be ascetic or take contraception since the signing of ICF to 24 weeks or later after the last administration of drug.
排除标准
- •Under pregnancy or lactation, or positive based on blood pregnancy test.
- •Severe allergic to related ingredients in the clinical trial.
- •Received any other investigational treatment within 28 days before the administration of HV-
- •History of other known malignant tumors within the previous 5 years.
- •Primary central nerve system (CNS) cancer, or Participants with CNS metastasis after localized treatment.
- •Participants with any active autoimmune disease, a history of autoimmune disease, or a history or syndrome requiring treatment with systemic steroids or immunosuppressive drugs.
- •Immunodeficiency including HIV positive, acquired or primary immunodeficiency.
- •Participants with ≥ grade 3 thromboembolic events within 6 months or under thrombolysis treatment.
- •Participants with hereditary or acquired hemorrhagic disease.
- •Participants with clinical cardiovascular disease or symptoms
- •Participants with active infection.
- •Participants with active pulmonary tuberculosis infection.
- •Participants with positive hepatitis B surface antigen or positive hepatitis B core antibody or positive hepatitis C virus antibody.
- •Treponema pallidum antibody positive.
- •Participants received major surgery or under severe injury within 28 days before HV-101 infusion.
- •Participants who received live vaccine or attenuated live vaccine 28 days before HV-101 infusion.
- •Participants who have drug addiction history, alcoholism, or drug users.
- •Participants who received cell therapy before enrollment.
- •Participants who have contraindications to the treatment of IL-2 injection.
- •Participants not suitable for the clinical trial evaluated by the investigators.
结局指标
主要结局
Safety of HV-101
时间窗: Day 0 - Day 730
The safety of HV-101 will be assessed based on the totality of dose-limiting toxicity (DLT) and adverse event (AE) data collected during this phase.
次要结局
- Overall survival (OS)(Day 0 - Day 730)
- Overall Response Rate (ORR)(Day 0 - Day 730)
- Duration of Response (DOR)(Day 0 - Day 730)
- Progression free survival (PFS)(Day 0 - Day 730)
- Disease Control Rate (DCR)(Day 0 - Day 730)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
ACT-TIL and ANV419 for Advanced Melanoma.Advanced MelanomaNCT05869539University Hospital, Basel, Switzerland10
招募中
1 期
A Study of GC101 TIL in Advanced Solid Tumors (TR)Advanced Solid TumorsNCT04967833Shanghai Juncell Therapeutics20
Unknown
1 期
Study on TIL for the Treatment of r/r Gynecologic TumorsGynecologic CancerNCT04766320Shanghai 10th People's Hospital15
招募中
1 期
A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)Gastrointestinal TumorNCT04960072Shanghai Juncell Therapeutics50
招募中
1 期
Study of GC101 TIL in Brain Glioma (Soochow2)GliomaNCT04943913Shanghai Juncell Therapeutics50